US stock futures steady with focus on Mideast tensions, Fed meeting

U.S. stock index futures edged higher Monday as easing oil prices calmed investor sentiment despite ongoing geopolitical tensions between Iran and Israel. Investors are closely watching the Federal Reserve's upcoming monetary policy decision on Wednesday, anticipating unchanged interest rates but focusing on Chair Powell's comments and updated economic projections for signals on potential rate cuts; Barclays strategists anticipate the Fed's dot plot will indicate delayed rate cuts, with potentially only one cut this year and three in 2026. In company news, Sarepta Therapeutics shares plunged after disclosing a second patient death related to its gene therapy, while U.S. Steel rose following Trump's approval of Nippon Steel's acquisition bid.

Analysis

U.S. stock index futures indicated a slight rebound on Monday, with S&P 500 E-minis up 0.4% and Nasdaq 100 E-minis rising 0.46%, as easing crude oil prices offered some relief to market sentiment despite persistent geopolitical tensions between Iran and Israel. Oil prices had surged 7% on Friday following mutual air strikes, fueling concerns over potential supply disruptions, but subsequently pulled back from January highs. The market's overarching focus shifts to the Federal Reserve's upcoming monetary policy decision on Wednesday, where interest rates are widely anticipated to be held steady. Investors will scrutinize Fed Chair Jerome Powell’s remarks and the central bank's updated economic projections for signals on the timing and extent of potential rate cuts. Current money market data, via CME Group’s Fedwatch tool, suggests traders are pricing in approximately 48 basis points of rate cuts by the end of 2025, with a 55% chance of a 25-basis-point reduction in September. However, Barclays strategists have offered a more tempered view, forecasting a "stagflationary flavor" with higher inflation and downgraded GDP growth in 2025, leading to delayed rate cuts, potentially only one in the current year and three in 2026. Key economic indicators, including monthly retail sales and import prices, are also due this week. In corporate developments, Sarepta Therapeutics (SRPT) shares plummeted 30% in premarket trading after the company reported a second patient death associated with its gene therapy. Conversely, U.S. Steel (X) shares saw a 5% increase following President Trump's approval of Nippon Steel’s $14.9 billion acquisition bid.

Key Decisions for Investors

• Investors should closely monitor the Federal Reserve's forthcoming statements and economic projections for clarity on the monetary policy trajectory, particularly concerning the timing and magnitude of anticipated rate cuts, given the divergence between current market pricing and some analyst forecasts.
• The significant 30% premarket decline in Sarepta Therapeutics (SRPT) shares due to adverse clinical trial news highlights the inherent high-risk, high-reward nature of biotechnology investments, warranting careful due diligence and risk assessment for exposure in this sector.
• Vigilance regarding geopolitical developments in the Middle East and their consequent impact on oil prices remains essential, as fluctuations in energy costs can significantly influence inflation outlooks and thereby Federal Reserve policy decisions.
• The 5% appreciation in U.S. Steel (X) shares following the approval of its acquisition offers an event-driven consideration, though investors should also weigh potential regulatory hurdles or other risks that could affect the $14.9 billion deal's completion.